Skip to main content

Top Bar Menu

Go to LUNGevity.org › Sign Up For Emails

  • Non-Small Cell Lung Cancer
    • NSCLC
    • ALK
    • EGFR
    • KRAS
    • Rare Mutations
  • Small Cell Lung Cancer
  • Resources
    • Clinical Trials
    • Find a Cancer Center
    • Resource Library
    • Podcast

Go to LUNGevity.org › Sign Up For Emails

Patient Gateways

Top Bar Menu

Go to LUNGevity.org › Sign Up For Emails

  • Non-Small Cell Lung Cancer
    • NSCLC
    • ALK
    • EGFR
    • KRAS
    • Rare Mutations
  • Small Cell Lung Cancer
  • Resources
    • Clinical Trials
    • Find a Cancer Center
    • Resource Library
    • Podcast

Main navigation

Close Menu
  • Clinical Trials
  • Clinical Trials
  • Clinical Trials
  • Clinical Trials
  • Clinical Trials
  • Clinical Trials

You are about to leave the Patient Gateway

You’re one click away from learning about one of our most valued sponsors. Read about how they’re making a difference in patients’ lives.

ProceedCancel

Patient Gateway

RSS Feed

  • NSCLC Feed
  • ALK Feed
  • EGFR Feed
  • KRAS Feed
  • Rare Mutations Feed
  • SCLC Feed
Comparative predictive performance of different eGFR equations for 1-year major adverse cardiovascular events after percutaneous coronary intervention in patients with acute coronary syndrome

Dynamic clonal evolution of multiple bypass resistance mechanisms in EGFR-mutant lung adenocarcinoma: a case report

Longitudinal ctDNA profiling to guide anti-EGFR rechallenge in metastatic colorectal cancer: a prospective single-arm phase II trial

HUTCHMED Reports Positive Phase 3 SANOVO Data For ORPATHYS Plus TAGRISSO In EGFR-Mutant NSCLC

赵艳秋教授解读TOP研究:EGFR敏感突变(Ex19del/L858R)-TP53共突变晚期NSCLC一线治疗高级别循证证据公布_腾讯新闻

Structural classification of EGFR mutations and its association with TKI efficacy against compound and co-mutations in a Chinese NSCLC cohort: a single-center retrospective analysis

A U‐Shaped Association: The First‐Year eGFR Slope and Mortality Risk in Multiple Myeloma

Practical Management in EGFR-Mutant NSCLC: Infusion Logistics, Skin Toxicity, and Quality of Life

Selecting Frontline Therapy for High-Risk EGFR-Mutated NSCLC

SHARE

The Patient Gateways are a project of LUNGevity Foundation, an organization transforming how people are diagnosed and live with lung cancer. Learn more here.

Privacy policy | Contact us

 

This website is not intended to, and does not, provide medical advice, professional diagnosis, opinion, treatment, or services. Medical information provided on this site is for informational and educational purposes only. After reading content from this website, you are encouraged to review the information carefully with your physician.

 

Copyright © 2026 LUNGevity Foundation. All rights reserved.